Sign in
CompletedPhase 3

A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age

Key facts

Who runs it
ModernaTX, Inc.
Where
Anderson, Austin, Baton Rouge, Beaumont, Birmingham, Bountiful, Brandon, Chamblee, Charlotte, Cleveland, Dallas, Doral, Endwell, Forest, Garden Grove, Grand Island, Greenville, Hialeah, Honolulu, Jacksonville, Knoxville, Lake Charles, Laredo, Las Vegas, Lilburn, Lincoln, Long Beach, Miami, Miami Lakes, Minneapolis, Modesto, Moore, Myrtle Beach, New York, Norcross, Norfolk, Omaha, Overland Park, Panorama City, Pomona, Portsmouth, Raleigh, Rockville, San Antonio, San Diego, Savannah, Sioux City, Spartanburg, Springdale, Springville, The Bronx, Tucson, Tustin, and Waterbury, United StatesSee the 62 sites
Trial code
Status
Completed
Phase
Phase 3
People taking part
3,317 people enrolled
Started
1 Apr 2022
Ended
8 Nov 2024
Type of study
Interventional, 7 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Placebo
  • mRNA-1345
  • Afluria® Quadrivalent
  • mRNA-1273.214
Record updated
30 December 2025

Who can take part

Age
50 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Parts A and B both:
  • Adults ≥50 years of age on the day of the Randomization Visit (Day 1) who are primarily responsible for self-care and activities of daily living. Participants may have one or more chronic medical diagnoses, but should be medically stable as assessed by: Absence of changes in medical therapy within 1 month due to treatment failure or toxicity; Absence of medical events qualifying as SAEs within 1 month of the planned vaccination on Day 1; and absence of known, current, and life-limiting diagnoses which, in the opinion of the investigator, would make completion of the protocol unlikely
  • Able to comply with study requirements, including access to transportation for study visits; Part B only:
  • Fully vaccinated for COVID-19 with an approved primary series according to the locally authorized or approved regimen. If the most recent COVID-19 vaccine was part of a primary series, it must be ≥ 150 days before (or less per local guidance) Day 1. If the most recent COVID-19 vaccine was a booster dose, it must be ≥ 120 days before (or less per local guidance) Day 1; Part C:
  • Participants at Part C study sites who have been enrolled in Part B (Groups 4 and 5) of this study; have immunogenicity blood sampling at Part B baseline and Day 29; completed the Day 211/end-of-study visits for Part B; were included in the per-protocol (PP) set; and received 1 dose of mRNA-1345 at least 12 months (but no later than 15 months) prior to the time of enrollment
  • Able to comply with study requirements, including access to transportation for study visits

Who cannot take part

  • Participant has received or plans to receive any vaccine authorized or approved by a local health agency ≤28 days prior to study injections (Day 1) or plans to receive a vaccine authorized or approved by a local health agency within 28 days after the study injections
  • Prior participation in research involving receipt of any investigational product (drug/biologic/device including any investigational RSV product) within 45 days before the planned date of the Day 1 study injection
  • Participant has received a seasonal influenza vaccine or any other investigational influenza vaccine ≤180 days prior to the Randomization Visit (Day 1)
  • History of a serious reaction to any prior vaccination, or Guillain-Barré syndrome within 6 weeks of any prior influenza immunization
  • Participated in an interventional clinical study within 28 days prior to the Screening Visit based on the medical history interview or plans to do so while participating in this study; Part B:
  • Participant has received or plans to receive any vaccine authorized or approved by a local health agency ≤ 28 days prior to study injections (Day 1) or plans to receive a vaccine authorized or approved by a local health agency within 28 days after the study injections (with the exception of SARS-Cov-2 vaccination)
  • Prior participation in research involving receipt of any investigational product (drug/biologic/device with the exception of RSV investigation products) within 45 days before the planned date of the Day 1 study injection
  • Prior receipt of any investigational/approved RSV product within 1 year of the Day 1 study injection
  • Has known history of SARS-CoV-2 infection within 90 days prior to enrollment; Parts A and B both:
  • Participation in another interventional clinical research study where participant has received an investigational product (drug/biologic/device) within 6 months before the planned date of the BD Day 1 study injection. Any prior receipt of an investigational or approved vaccine against RSV, except as part of mRNA-1345 Study P302 Part B, is exclusionary
  • Participant has received or plans to receive any vaccine authorized or approved by a local health agency ≤28 days prior to the study injection (BD Day 1) or plans to receive a vaccine authorized or approved by a local health agency within 28 days after the study injections
  • History of a serious reaction to any prior vaccination or Guillain-Barré syndrome 6 weeks after any prior influenza immunization; Other inclusion and/or exclusion criteria may apply
  • Participant had significant exposure to someone with SARS-CoV-2 infection or COVID-19 in the past 10 days, as defined by the United States (US) Centers for Disease Control and Prevention (CDC) as a close contact of someone who has had COVID-19; Part C:
  • Part A:

Where in United States

  • Velocity Clinical Research - Anderson - ERN - PPDSAnderson, United States
  • Benchmark Research - Austin - HyperCore - PPDSAustin, United States
  • Meridian Clinical Research (Baton Rouge-Louisiana) - Platinum - PPDSBaton Rouge, United States
  • Tekton Research - Beaumont - Platinum - PPDSBeaumont, United States
  • Central Research Associates, IncBirmingham, United States
  • Cope Family Medicine Ogden ClinicBountiful, United States
  • Teradan Clinical TrialsBrandon, United States
  • Tekton Research - Georgia - Platinum - PPDSChamblee, United States
  • Javara Research Inc. - Charlotte - Javara - PPDSCharlotte, United States
  • Velocity Clinical Research - Cleveland - ERN - PPDSCleveland, United States
  • Zenos Clinical ResearchDallas, United States
  • Dolphin Medical ResearchDoral, United States
  • Revival Research Corporation - Clinedge - PPDSDoral, United States
  • Meridian Clinical Research (Endwell-New York) - Platinum - PPDSEndwell, United States
  • Javara Inc./Privia Medical Group INCForest, United States
  • Paragon RX Clinical, Inc.Garden Grove, United States
  • Meridian Clinical Research (Grand Island) - Platinum - PPDSGrand Island, United States
  • Velocity Clinical Research - Greenville - ERN - PPDSGreenville, United States
  • Indago Research and Health CenterHialeah, United States
  • East-West Medical Research InstituteHonolulu, United States
  • Westside Center for Clinical Research - ERN - PPDSJacksonville, United States
  • New Phase Research & DevelopmentKnoxville, United States
  • Clinical Trials of SWLA, LLCLake Charles, United States
  • Milton Haber, M.D.Laredo, United States
  • Clinical Research Center of Nevada - ERN - PPDSLas Vegas, United States
  • Santa Rosa Medical Centers of Nevada/ CCT ResearchLas Vegas, United States
  • Lifeline Primary Care/ CCT ResearchLilburn, United States
  • Be Well Clinical Studies LLCLincoln, United States
  • Meridian Clinical Research, LLC (Lincoln Nebraska) - Platinum - PPDSLincoln, United States
  • Ark Clinical ResearchLong Beach, United States
  • Long Beach Clinical Trials, LLC (Site 1)Long Beach, United States
  • Long Beach Clinical Trials, LLC (Site 2)Long Beach, United States
  • Suncoast Research Associates LLC - ERN - PPDSMiami, United States
  • Suncoast Research Group LLC - ERN-PPDSMiami, United States
  • Floridian Clinical Research - ClinEdge - PPDSMiami Lakes, United States
  • Clinical Research Institute, Inc - CRN - PPDSMinneapolis, United States
  • Central Valley Research, LLCModesto, United States
  • Tekton ResearchMoore, United States
  • Trial Management Associates LLC - ERN - PPDSMyrtle Beach, United States
  • IMA Medical Research, PC.New York, United States
  • Georgia Clinic / CCT ResearchNorcross, United States
  • Meridian Clinical ResearchNorfolk, United States
  • Meridian Clinical Research (Omaha-Nebraska) - Platinum - PPDSOmaha, United States
  • Midwest Regional Health Services - CCT ResearchOmaha, United States
  • Meridian Clinical Research, LLC (Overland Park, Kansas) - Platinum - PPDSOverland Park, United States
  • Velocity Clinical Research, Panorama CityPanorama City, United States
  • Empire Clinical ResearchPomona, United States
  • Meridian Clinical Research - Family Practice Ports - Portsmouth - Platinum - PPDSPortsmouth, United States
  • M3 Wake Research, Inc - M3 WR - ERN - PPDSRaleigh, United States
  • Meridian Clinical Research (Rockville Maryland) - Platinum - PPDSRockville, United States
  • Sun Research InstituteSan Antonio, United States
  • Acclaim Clinical ResearchSan Diego, United States
  • Medical Center For Clinical Research - M3 WR - ERN - PPDSSan Diego, United States
  • Meridian Clinical Research (Savannah Georgia) - Platinum - PPDSSavannah, United States
  • Meridian Clinical Research (Sioux City - Iowa)Sioux City, United States
  • Velocity Clinical Research - Spartanburg - ERN - PPDSSpartanburg, United States
  • Meridian Clinical Research - Cincinnati - Platinum - PPDSSpringdale, United States
  • CCT Research at Springville DermatologySpringville, United States
  • CHEAR Center LLC - ClinEdge - PPDSThe Bronx, United States
  • Del Sol Research Management - ClinEdge - PPDSTucson, United States
  • Ark Clinical ResearchTustin, United States
  • Chase Medical Research, LLCWaterbury, United States

About the trial

What the trial wants to find out

The main purposes of Part A of this study are to evaluate the safety, tolerability, and immunogenicity of mRNA-1345 coadministered with a seasonal influenza vaccine (Afluria® Quadrivalent); to evaluate the impact of coadministered influenza vaccine on the immune response to RSV-A; and to evaluate the impact of coadministered RSV vaccine on the immune response to influenza.

Read full original descriptionShow less

The main purposes of Part B of this study are to evaluate the safety, tolerability, and immunogenicity of mRNA-1345 coadministered with mRNA-1273.214; to evaluate the effect of coadministered mRNA-1273.214 on the immune response to RSV-A; and to evaluate the effect of coadministered RSV vaccine on the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

The main purposes of Part C (single arm, open-label) of this study are to evaluate the safety and tolerability of a booster dose (BD) of mRNA-1345 administered at 1 Year following a primary dose; to evaluate the immune response to RSV-A of a BD of mRNA 1345 administered at 1 Year following a primary dose; and to evaluate the immune response to RSV-B of a BD of mRNA-1345 administered at 1 Year following a primary dose.

The 7 groups in the trial

  • Part A: mRNA-1345 + PlaceboTreatment being tested

    Single injection of mRNA-1345 and placebo, administered intramuscularly (IM), one in each arm on Day 1.

    Treatment: Placebo and mRNA-1345

  • Part A: mRNA-1345 + Afluria® QuadrivalentTreatment being tested

    Single injection of mRNA-1345 and Afluria® quadrivalent, administered IM, one in each arm on Day 1.

    Treatment: mRNA-1345 and Afluria® Quadrivalent

  • Part A: Afluria® Quadrivalent + PlaceboExisting treatment, for comparison

    Single injection of Afluria® quadrivalent and placebo, administered IM, one in each arm on Day 1.

    Treatment: Placebo and Afluria® Quadrivalent

  • Part B: mRNA-1345 + PlaceboTreatment being tested

    Single injection of mRNA-1345 and placebo, administered IM, one in each arm on Day 1. An additional injection of mRNA-1273.214, administered on Day 29.

    Treatment: Placebo, mRNA-1345, and mRNA-1273.214

  • Part B: mRNA-1345 + mRNA-1273.214Treatment being tested

    Single injection of mRNA-1345 and mRNA-1273.214, administered IM, one in each arm on Day 1. An additional injection of placebo administered on Day 29.

    Treatment: Placebo, mRNA-1345, and mRNA-1273.214

  • Part B: mRNA-1273.214 + PlaceboExisting treatment, for comparison

    Single injection of mRNA-1273.214 and placebo, administered IM, one in each arm on Day 1. An additional injection of placebo administered on Day 29.

    Treatment: Placebo and mRNA-1273.214

  • Part C: mRNA-1345Treatment being tested

    Single injection of mRNA-1345 administered IM on BD Day 1.

    Treatment: mRNA-1345

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered With a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults ≥ 50 Years of Age
Publications
Record updated
30 December 2025